{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:01:31Z","timestamp":1790085691785,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7212029"],"award-info":[{"award-number":["7212029"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7212030"],"award-info":[{"award-number":["7212030"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.msard.2021.103181","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T02:14:02Z","timestamp":1627697642000},"page":"103181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis"],"prefix":"10.1016","volume":"55","author":[{"given":"Yupeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxiao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9451","key":"10.1016\/j.msard.2021.103181_bib0001","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis[J]","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.103181_bib0002","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models[J]","volume":"27","author":"Wu","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2021.103181_bib0003","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice[J]","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"issue":"10206","key":"10.1016\/j.msard.2021.103181_bib0004","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial[J]","volume":"394","author":"Cree","year":"2019","journal-title":"The Lancet"},{"issue":"3_suppl","key":"10.1016\/j.msard.2021.103181_bib0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1191\/0961203305LU2109OA","article-title":"Mechanisms of action of mycophenolate mofetil[J]","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.msard.2021.103181_bib0006","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder[J]","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103181_bib0007","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2016.09.035","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study[J]","volume":"370","author":"Xu","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2021.103181_bib0008","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/WNF.0000000000000131","article-title":"The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China[J]","volume":"39","author":"Chen","year":"2016","journal-title":"Clin. Neuropharmaco."},{"issue":"1","key":"10.1016\/j.msard.2021.103181_bib0009","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder[J]","volume":"24","author":"Chen","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2021.103181_bib0010","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders[J]","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"14","key":"10.1016\/j.msard.2021.103181_bib0011","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1177\/1352458516687403","article-title":"Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders[J]","volume":"23","author":"Kim","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"4","key":"10.1016\/j.msard.2021.103181_bib0012","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ajo.2006.08.010","article-title":"Revised diagnostic criteria for neuromyelitis optica[J]","volume":"142","author":"Wingerchuk","year":"2006","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.msard.2021.103181_bib0013","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2021.103181_bib0014","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"issue":"11","key":"10.1016\/j.msard.2021.103181_bib0015","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis[J]","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"issue":"9","key":"10.1016\/j.msard.2021.103181_bib0016","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients[J]","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2021.103181_bib0017","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy[J]","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2021.103181_bib0018","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder[J]","volume":"385","author":"Yang","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2021.103181_bib0019","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-018-1056-x","article-title":"Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study[J]","volume":"18","author":"Jiao","year":"2018","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2021.103181_bib0020","first-page":"9","article-title":"Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: a Prospective Multicenter Study in South China[J]","author":"Huang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2021.103181_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101413","article-title":"Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia[J]","volume":"36","author":"Drulovic","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2021.103181_bib0022","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-019-09649-7","article-title":"Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study[J]","volume":"267","author":"Shi","year":"2020","journal-title":"J. Neurol."},{"issue":"15","key":"10.1016\/j.msard.2021.103181_bib0023","doi-asserted-by":"crossref","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","article-title":"Evaluation of efficacy and tolerability of first-line therapies in NMOSD[J]","volume":"94","author":"Poupart","year":"2020","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2021.103181_bib0024","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","article-title":"Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success[J]","volume":"18","author":"Greenberg","year":"2012","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2021.103181_bib0025","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial[J]","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2021.103181_bib0026","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial[J]","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.103181_bib0027","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder[J]","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103181_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102166","article-title":"Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: evidence from Randomized Controlled Trials[J]","volume":"43","author":"Xue","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2021.103181_bib0029","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints[J]","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.103181_bib0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.msard.2019.05.011","article-title":"Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis[J]","volume":"33","author":"Espiritu","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103181_bib0031","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.msard.2019.08.009","article-title":"Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis[J]","volume":"35","author":"Huang","year":"2019","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482100448X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482100448X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T03:30:51Z","timestamp":1786764651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482100448X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":31,"alternative-id":["S221103482100448X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103181","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103181"}}